Véronique Gelsi Boyer
Affiliation: Institut Paoli-Calmettes
Gelsi Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci M, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5:12 pubmed publisher
..They are generally associated with signs of aggressiveness and poor clinical outcome. Because of this, a systematic determination of ASXL1 mutational status in myeloid malignancies should help in prognosis assessment...
Gelsi Boyer V, Cervera N, Bertucci F, Brecqueville M, Finetti P, Murati A, et al
. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Haematologica. 2013;98:576-83 pubmed publisher
Gelsi Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, et al
. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151:365-75 pubmed publisher
..The overall survival of ASXL1 mutated patients was lower than that of unmutated patients. ..
Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, et al
. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010;10:401 pubmed publisher
Gelsi Boyer V, Trouplin V, Adélaïde J, Aceto N, Remy V, Pinson S, et al
. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer. 2008;8:299 pubmed publisher
..We detected RAS pathway mutations and RUNX1 alterations. The latter included a new cryptic USP16-RUNX1 fusion. In some samples, two alterations coexisted already at this early chronic stage. ..